20
Participants
Start Date
June 30, 2006
Primary Completion Date
May 31, 2009
Study Completion Date
May 31, 2009
Thymoglobulin
1.5 mg/kg by vein on Days -11 to -7.
Total Lymphoid Irradiation
80 cGy daily on days -11 to -7 and -4 to 0.
Peripheral Blood Stem Cell Infusion
PBSC infusion administered on day 0.
Rituximab
375 mg/m\^2 by vein on days -13, -6, 1, \& 8. Only those patients whose tumors express CD20 will receive Rituximab.
U.T.M.D. Anderson Cancer Center, Houston
Genzyme, a Sanofi Company
INDUSTRY
M.D. Anderson Cancer Center
OTHER